Clinical Trial Update: IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for IMA970A plus CV8102 in very early to intermediate hepatocellular carcinoma has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CV8102 (CV8102)
• IMA970A

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED